Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.95 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.95 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.95 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.95 |
| ▸ | EGFR known ✓ | P00533 | 5/20 | 0.47 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.47 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.46 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.46 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.46 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.46 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.43 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25620 | 0.98 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPI4KA | |
| SCHEMBL29461423 | 0.98 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPI4KA | |
| Water SCHEMBL28234954 | 0.95 | PDE4A (0.95) | PDE4APDE4BPDE4CPDE4DPI4KA | |
| Benzene SCHEMBL11180826 | 0.95 | PDE4A (0.95) | PDE4APDE4BPDE4CPDE4DPI4KA | |
| Quinoxaline SCHEMBL27447866 | 0.90 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DPI4KA | |
| SCHEMBL28863471 | 0.85 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DPI4KA | |
| Acetic Acid SCHEMBL29289401 | 0.85 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DPI4KA | |
| SCHEMBL28062169 | 0.83 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DPI4KA | |
| SCHEMBL28062205 | 0.80 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Ethoxycarbonyl Group SCHEMBL27845970 | 0.77 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104374846-A | Efficient liquid chromatography of fenazaquin residue in plant-derived foods | PONY TESTING TECHNOLOGY TIANJIN CO LTD | 2015-02-25 | — | — | CN | disclosed |
| CN-102914607-A | High performance liquid chromatography method for measuring residual amount of Fenazaquin in plant-derived food | PONY TEST TECHNOLOGY TIANJIN CO LTD | 2013-02-06 | — | — | CN | disclosed |
| US-6897214-B2 | Quinazoline derivatives | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| EP-0880507-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| CN-1142919-C | Quinazoline derivatives as antitumor agents | — | 2004-03-24 | — | — | CN | disclosed |
| US-20030018029-A1 | Quinazoline derivatives | ZENECA LIMITED | 2003-01-23 | — | — | US | disclosed |
| US-6399602-B1 | ANTICANCER AGENTS | ZENECA LIMITED (GB) | 2002-06-04 | — | — | US | disclosed |
| CN-1052379-C | Quinazoline derisatives | DOWELANCO (US) | 2000-05-17 | — | — | CN | disclosed |
| CN-1211240-A | Quinazoline derivatives as antitumor agents | ZENECA LTD (GB) | 1999-03-17 | — | — | CN | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| EP-0326329-B1 | Quinazoline derivatives useful as insecticides. | DOW AGROSCIENCES LLC (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| US-5411963-A | Plant fungicides, miticides, insecticides | DOWELANCO (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0380264-A2 | Halogenation process | DowElanco (US) | 1990-08-01 | — | — | EP | disclosed |
| CN-1035825-A | Quinazoline derivant | LILLY CO ELI (US) | 1989-09-27 | — | — | CN | disclosed |
| EP-0326329-A2 | Quinazoline derivatives | DowElanco (US) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018029-A1 | Quinazoline derivatives | ABL1, FGFR1, ERBB2 | PDE4A 3441/4885PDE4B 3326/4885PDE4C 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.